1. Atossa collaborates with Insilico on (Z)-endoxifen for glioblastoma treatment. 2. The study identifies (Z)-endoxifen as a potential therapy for GBM. 3. AI analyses find shared genes between GBM and endoxifen-treated cells. 4. In vitro studies show (Z)-endoxifen surpassed temozolomide in effectiveness. 5. Market opportunity expands for Atossa with new oncology indications.
FAQ
Why Bullish?
This collaboration opens new treatment avenues for a previously underserved indication, which can significantly enhance ATOS's market prospects and investor interest, akin to past successes seen with similar biotech advancements. Companies that successfully repurpose existing drugs often experience notable stock price increases due to diminished development risks and immediate therapeutic applicability.
How important is it?
This article highlights significant advancements in Atossa's research with endoxifen, introducing a new potential indication in glioblastoma, likely driving investor confidence and engagement. Such collaborations and findings typically lead to increased visibility and investment in companies with strong clinical-stage pipelines.
Why Long Term?
While immediate market reactions may be positive, the full impact of these findings and their subsequent commercialization will take time. Historical examples, like those seen with oncology drugs gaining new indications, have taken years to translate from research into successful market launches.
Atossa Therapeutics and Insilico Medicine Publish Study on (Z)-Endoxifen for Glioblastoma
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company, has partnered with Insilico Medicine, a leader in AI-powered drug discovery, to publish a study investigating the therapeutic potential of (Z)-endoxifen for glioblastoma multiforme (GBM). This comprehensive research, recently featured in Nature Scientific Reports, aims to explore new oncology indications for endoxifen, potentially one of the most promising candidates for treating one of the most aggressive forms of brain cancer.
Study Findings on (Z)-Endoxifen
(Z)-Endoxifen is an active metabolite of tamoxifen, which has shown activity in endocrine-resistant breast cancer. The study utilized Insilico's AI-powered PandaOmics platform to evaluate over 900 cancer indications and identify GBM as a significant candidate for treatment exploration. The results reveal critical insights into the workings of endoxifen as a therapeutic option for GBM.
Significance of the Research
The publication sheds light on GBM, known for its extremely low five-year survival rate of approximately 4%. By employing various AI-enabled methodologies, including transcriptomic integration and computational modeling, the study provides a foundational understanding of how (Z)-endoxifen could disrupt the biological processes contributing to tumor growth and resistance. Key findings include:
- Identification of over 1,400 genes shared between GBM tumors and endoxifen-treated cells.
- Reversal of biological programs driving uncontrolled tumor proliferation and aggressive behavior.
- Significant suppression of GBM cell proliferation in laboratory tests, surpassing the effectiveness of traditional treatments like temozolomide.
Collaboration Highlights
Steven Quay, M.D., Ph.D., CEO of Atossa Therapeutics, emphasized the importance of this collaboration, stating, "This collaboration with Insilico Medicine provides a whole new indication in which we might explore the utility of endoxifen, addressing an extremely underserved set of cancer patients." Dr. Quay noted that while the focus has primarily been on women's health, this research marks a significant expansion into glioblastoma exploration.
Future Implications and Laboratory Validation
The laboratory findings closely aligned with the study's computational predictions. In vitro results demonstrated that (Z)-endoxifen induced apoptosis and exhibited greater cytotoxicity than high-dose temozolomide. Moreover, in vivo studies confirmed the tolerability of endoxifen across various doses, solidifying its potential as a therapeutic candidate for GBM.
About the Collaborating Companies
Atossa Therapeutics is focused on developing innovative therapies aimed at significant unmet medical needs in breast cancer. Its approach involves judicious capital allocation towards viable programs, enhancing future regulatory submission potential. The company's stock is traded under the symbol ATOS.
Insilico Medicine leverages cutting-edge AI technologies to enhance the drug discovery process, significantly shortening traditional timelines. The firm has secured 20 preclinical candidates between 2021 and 2024, attaining an impressive turnaround of just 12 to 18 months for each program.
Conclusion
This joint publication signals a significant step forward in exploring new therapeutic avenues for glioblastoma, showcasing how AI-enabled discovery can unlock potential in well-established drug compounds like (Z)-endoxifen. The ongoing partnership between Atossa Therapeutics and Insilico Medicine holds promise for advancing cancer treatment innovations.